ShareProphets : keywords

TRX

PREMIUM CONTENT

Tissue Regenix – 2022 results, is it “achieving strong commercial traction”?

Previously writing on regenerative medical device group Tissue Regenix (TRX), I noted argues distribution agreement ‘delight’. How’s that balance sheet now?. The group has now announced results for the 2022 calendar year, arguing they with it “having delivered on its strategy for growth whilst achieving strong commercial traction”. What does that actually mean financially though?

Subscribe to ShareProphets to access Premium Content

By Steve Moore
189 days ago

TRX

Tissue Regenix – “product launch” & “distribution agreement”, ramptastic?

Regenerative medical device company Tissue Regenix (TRX) states “following the successful launch of VNEW with ARMS Medical in September 2021, we are very pleased to be continuing our partnership and launching the VNEW Fascia Lata allograft for surgical procedures to support tissue”. So what of a share price response slightly lower to 0.575p?

By Steve Moore
293 days ago

TRX

Tissue Regenix – a “pleased to confirm” re. cyber security incident, but still what about the balance sheet of this Woodford pick?

Shares in ‘regenerative medical devices’ group Tissue Regenix (TRX) are currently approaching 20% higher on the day, at around 1.20p, on the back of an update including “it is anticipated that delayed orders will be dispatched over the coming weeks… All processing in the company's United States facility has also resumed with immediate effect”…

By Steve Moore
1330 days ago

TRX

Tissue Regenix – the nightmare continues for Neil Woodford investors!

The 10th September-announced half-year results from “regenerative medical devices” group Tissue Regenix (TRX) included “we anticipated that the year would be significantly weighted towards the second half, as announced on the 4 June… We continue to expect that this will be the case… demand for our products is strong”. Now a “Trading Update”…